Migraine is three times more common in women than men, and the gap is widest during the reproductive years. Estrogen directly modulates the trigeminovascular system and pain processing pathways in ways that make migraine attacks more likely when estrogen levels change rapidly.

Perimenopause is often the worst period for migraine in a woman's life. For women who have had migraines since adolescence, attacks may become more frequent, longer, and harder to treat. Some women experience migraines for the first time during perimenopause. Understanding why this happens also explains the trajectory that follows.

Fluctuation, Not Level, Is the Trigger

Research on migraine susceptibility during the menopausal transition has found that attacks are driven by the rate of estrogen change, not by absolute estrogen levels.[1]

Women with migraines did not have consistently higher or lower estrogen than those without. What differed was the rate of estrogen withdrawal in the late luteal phase of each cycle. This aligns with the estrogen withdrawal hypothesis: migraine attacks are triggered when estrogen falls below approximately 45–50 pg/mL after a sustained period of higher levels.[2]

During perimenopause, estrogen becomes unpredictably erratic. It can surge well above premenopausal baseline one week and drop sharply the next. These rapid swings create repeated withdrawal triggers throughout the month, regardless of where a woman is in her cycle. Women who previously had migraine only at menstruation may find it occurring at other times for this reason.

What Happens After Menopause

Once estrogen stabilises at a consistently low level after the final menstrual period, the fluctuation that triggers withdrawal migraines is reduced. Studies consistently show that women with migraine without aura frequently see improvement in frequency and severity in the postmenopausal years.[3] The erratic hormonal environment resolves, and the withdrawal trigger with it.

Women with migraine with aura have a more complex picture. Their migraines may also improve, but they carry a twofold increased risk of ischemic stroke independent of other risk factors.[4] This background risk shapes the risk-benefit calculation for HRT.

Managing Migraines During Perimenopause

Transdermal estradiol. For women whose migraines are tied to estrogen fluctuations, stabilising levels with continuous transdermal estradiol can reduce attack frequency. Oral estrogen creates peaks and troughs with each dose and tends to worsen hormonally-triggered migraines. Transdermal delivery (patches, gels) provides more stable levels and is the recommended route when HRT is considered for migraine management.[3][5]

The key principle: continuous dosing without hormone-free intervals prevents the withdrawal events that trigger attacks.

Migraine with aura and HRT. Migraine with aura does not absolutely contraindicate physiological doses of transdermal estradiol, unlike combined oral contraceptives, where ethinylestradiol significantly increases stroke risk.[4] However, HRT users who experience an increase in migraine severity, including more frequent aura, show increased odds of ischemic stroke, and the decision requires careful individual risk assessment.[5]

Acute treatment. Perimenopausal migraines tend to be longer and more resistant to treatment than episodic attacks. Triptans are the most evidence-backed acute option. Long-acting triptans (frovatriptan, naratriptan) are useful for prevention of predictable hormone-related attacks because they can be started before the anticipated withdrawal window.[3]

Preventive medication. For women with frequent attacks that impair function, migraine preventives (beta-blockers, topiramate, amitriptyline, or CGRP monoclonal antibodies) are appropriate. These work independently of hormonal management and can be used alongside or instead of hormonal approaches.

When a Changing Migraine Pattern Warrants Evaluation

A headache that has changed in character, frequency, or location deserves clinical attention, not assumption that it is the same migraine as before. New-onset severe headache in midlife, particularly if different from previous headaches or accompanied by neurological symptoms, should be evaluated rather than attributed to hormonal change.

For most women, the trajectory follows a pattern: perimenopause worsens the frequency and severity of hormonally-driven migraine, and postmenopause brings gradual improvement. The years in between are the period that most warrants active management.

References

[1] Aegidius, K. L., Zwart, J. A., Hagen, K., Schei, B., Stovner, L. J. (2007). Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. European Journal of Neurology, 14(1), 73-78. See also: Migraine during perimenopause. https://pmc.ncbi.nlm.nih.gov/articles/PMC4759136/

[2] MacGregor, E. A. (2023). Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence. Cephalalgia, 43(10). https://pmc.ncbi.nlm.nih.gov/articles/PMC10512516/

[3] Pavlović, J. M. (2021). Menstrual and perimenopausal migraine: A narrative review. Headache, 60(10). https://pubmed.ncbi.nlm.nih.gov/33158484/

[4] Kurth, T., Schürks, M., Logroscino, G., Gaziano, J. M., Buring, J. E. (2010). Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ, 341, c3621. See also: Migraine with aura and stroke risk. https://pmc.ncbi.nlm.nih.gov/articles/PMC7948327/

[5] MacGregor, E. A. (2018). Migraine, menopause and hormone replacement therapy. Post Reproductive Health, 24(1), 11-18. https://pubmed.ncbi.nlm.nih.gov/28994639/